Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 8391-8400 Newer>

Pharmaceutical Executive August 1, 2012	Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency.
Pharmaceutical Executive August 1, 2012 Debbie Warner	Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder.
Pharmaceutical Executive August 1, 2012 Jill Wechsler	Fleshing Out FDASIA Medical apps, e-submissions, counterfeit drugs, and imports tucked into fairly "clean" user-fee renewal legislation. In late June leading legislators reached across party lines to quickly approve the Food and Drug Administration Safety and Innovation Act.
Pharmaceutical Executive August 1, 2012 Stan Bernard	Creallaborations: Pharma Starts Thinking Outside the Pill Box Creative non-pharmaceutical partnerships can offer innovators unique capabilities against the competition in a new era where challenges to market leadership are coming from every direction.
Pharmaceutical Executive August 1, 2012 Andrea Sobrio	Innovative Contracting: What is the Verdict? Industry is finding it harder to secure market access and payer uptake for new products. Innovative contracting may offer a solution. Is it working?
Pharmaceutical Executive August 1, 2012 Carol Ann Williams	Data Exclusivity: Making the Case As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Pharmaceutical Executive August 1, 2012 Julian Upton	Brand Building -- Not! As a drug company promoting a drug free Olympiad, GSK wins our gold hands down for finally putting the industry's best face forward on the last frontier of advertising and the TV sets of Europe.
Pharmaceutical Executive August 1, 2012 Leela Barham	The Queen's English Defining the language of value based pricing in the United Kingdom and ultimately the world.
Pharmaceutical Executive August 1, 2012 Wendy Balter	New Approaches to Medical Education Planning Promotional medical education planning used to be able to focus on the science first, without much consideration for delivery channels. Now technology expertise and channel considerations demand an equal share in up-front planning.
Pharmaceutical Executive August 1, 2012 William Looney	The Phrase that Plays The FDA is creatively applying regulatory fiat to force fundamental changes in company culture.
<Older 8391-8400 Newer> Return to current articles.